Nov '23

Evaluation of DermSat-7 for Assessing Treatment Satisfaction in … – JAMA Network

Question  Is the DermSat-7, a 7-item questionnaire specific for dermatological conditions, adequate for assessing treatment satisfaction in patients with acne?
Findings  In this cross-sectional study of 142 adults taking acne medication, the DermSat-7 had good structural validity and internal consistency for each of its 3 domains (effectiveness, convenience, and overall satisfaction). The effectiveness and overall satisfaction domains had stronger evidence for construct validity as assessed by convergent and known-groups validity testing.
Meaning  Findings of this study suggest that the DermSat-7, particularly the effectiveness and overall satisfaction domains, might be an effective tool for measuring treatment satisfaction in patients with acne.
Importance  Treatment satisfaction is important to achieving therapeutic success in patients with inflammatory dermatological diseases, such as acne.
Objective  To evaluate the structural validity, internal consistency, and construct validity of the DermSat-7, a questionnaire-based measure of treatment satisfaction, in patients with acne seen in routine clinical practice.
Design, Setting, and Participants  This cross-sectional study included adults with acne who were fluent in English and treated at an outpatient clinic at Brigham and Women’s Hospital between July 2022 and May 2023. At each visit, patients completed a self-administered, patient-reported outcome questionnaire, including a patient global assessment (PGA) of their acne severity and the DermSat-7. The DermSat-7 consists of 7 items assessing 3 domains of treatment: effectiveness (3 items), convenience (3 items), and overall satisfaction (1 item). At subsequent visits, patients were asked an anchor item related to change in disease severity (“How has your acne changed compared to your last visit?”) that was scored on a 7-point scale (–3 = much worse to 3 = much better). Also at each visit, a dermatologist completed the Comprehensive Acne Severity Scale (CASS).
Main Outcomes and Measures  The main outcomes were structural validity (assessed by factor analysis), internal consistency (assessed by Cronbach α), and construct validity (assessed using linear regression models and Pearson correlation coefficients).
Results  The analysis included 142 patients with acne (mean [SD] age, 25.1 [5.1] years; 96 females [67.6%]) taking acne medication who completed the DermSat-7. Exploratory factor and confirmatory factor analysis supported the unidimensionality of the 3 DermSat-7 domains. Cronbach α values of 0.89 and 0.80 supported good internal consistency in the effectiveness and convenience domains, respectively. Known-groups validity was supported by increasing DermSat-7 effectiveness and overall satisfaction scores with increasing levels of positive change in disease severity (linear regression coefficient, 7.51; 95% CI, 4.94-10.08; P < .001). Construct validity was further supported by moderate correlations with the anchor, PGA, and CASS scores (effectiveness domain: anchor r = 0.567, PGA r = –0.538, and CASS r = –0.485; overall satisfaction domain: anchor r = 0.467, PGA r = –0.486, and CASS r = –0.489).
Conclusion and Relevance  This cross-sectional study found that the DermSat-7 may be an effective tool for measuring treatment satisfaction, particularly effectiveness and overall satisfaction domains, among patients with acne. Further research is needed to examine additional measurement properties of the DermSat-7, such as content validity and interpretability, as well as to validate the DermSat-7 in other populations of patients with acne.
Shields A, Armstrong AW, Kaur MN, et al. Evaluation of DermSat-7 for Assessing Treatment Satisfaction in Patients with Acne. JAMA Dermatol. Published online November 22, 2023. doi:10.1001/jamadermatol.2023.4481
© 2023
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
© 2023 American Medical Association. All Rights Reserved.
Terms of Use| Privacy Policy| Accessibility Statement| Cookie Settings




Joker has been buying and selling domains since the late 90's. He has worked with many portfolios and investors over the past decade as well.

Leave a Reply

Your email address will not be published. Required fields are marked *